Last updated on March 2018

A Phase 3 clinical study for patients with Active Systemic Lupus Erythematosus

Brief description of study

The purpose of this study is to characterise long-term safety and tolerability of intravenous anifrolumab.

Detailed Study Description

This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled extension study to characterising the long term safety and tolerability of of an intravenous treatment regimen of anifrolumab versus placebo in subjects with moderately to severely active systemic lupus erythematosus who completed a Phase 3 study (D3461C00004 or D3461C00005) through the 52-week double-blind treatment period.

Clinical Study Identifier: NCT02794285

Contact Investigators or Research Sites near you

Start Over

AstraZeneca Clinical Study Information Center

Research Site
Nadarzyn, Poland
  Connect »